Home
About
Overview
Sharing Data
ORCID
Help
History (4)
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.
Maximiscin Induces DNA Damage, Activates DNA Damage Response Pathways, and Has Selective Cytotoxic Activity against a Subtype of Triple-Negative Breast Cancer.
McNall-Knapp, Rene
Peritoneal Absorption
See All 4 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clin Appl Thromb Hemost. 2019 Jan-Dec; 25:1076029619886022.
View in:
PubMed
subject areas
Administration, Oral
Aged
Anticoagulants
Double-Blind Method
Factor Xa Inhibitors
Female
Humans
Middle Aged
Risk Factors
Rivaroxaban
Venous Thromboembolism
authors with profiles
Gary E Raskob